Trastuzumab Deruxtecan

證據等級: L5

預測適應症: 1 個

Trastuzumab Deruxtecan: From Undocumented Original Indication to Drug-Induced Osteoporosis

One-Sentence Summary

The original approved indication for trastuzumab deruxtecan is not documented in the current evidence pack. The TxGNN model predicts a possible association with Drug-Induced Osteoporosis, but this signal is currently supported by 0 clinical trials and 0 publications — it is a pure computational prediction with no corroborating real-world evidence.

Quick Overview

Item	Content
Original Indication	Not documented in current dataset
Predicted New Indication	Drug-Induced Osteoporosis
TxGNN Prediction Score	99.31%
Evidence Level	L5
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on the information present in the evidence pack, trastuzumab deruxtecan is identified as a HER2-targeted antibody-drug conjugate (ADC), but no original indication record exists in this dataset for comparison against the predicted new indication.

The evidence pack’s own mechanistic assessment is notably skeptical of this prediction: there is no known biological pathway linking HER2 signaling to bone metabolism regulation (the RANKL/OPG axis), and no established connection between HER2-targeted therapy and drug-induced osteoporosis. The assessment explicitly flags this association as likely arising from embedding-level noise in the TxGNN knowledge graph rather than reflecting genuine biological plausibility.

Given the absence of an original indication for comparison, the absence of MOA detail, and the explicit noise-signal caveat in the source rationale, this prediction should be treated as exploratory only and not as a basis for further pharmacological reasoning at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

US Market Information

This drug currently has no market authorization records (market status: Not Marketed; total licenses: 0). No NDA/product information is available in the evidence pack.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (HER2-directed antibody-drug conjugate)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Cytotoxic-payload-bearing ADC; handling per institutional hazardous drug protocols is expected, pending confirmation from official labeling

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction carries only L5 evidence (model output with no supporting clinical trials or literature), the drug has no market authorization on record, and the source rationale itself identifies the mechanistic link as likely noise. Combined with blocking data gaps in safety labeling (TFDA/label warnings and contraindications), this candidate cannot proceed past initial screening (S0).

To proceed, the following is needed:

Original approved indication(s) for trastuzumab deruxtecan (currently missing)
Confirmed mechanism of action detail from DrugBank or official labeling
TFDA/FDA label warnings, contraindications, and drug interaction data (currently blocking data gap)
Independent mechanistic or preclinical evidence linking HER2-ADC therapy to bone metabolism/osteoporosis before any further evaluation is warranted
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.